0.24%
6.09%
20.78%
-2.01%
20.95%
135.51%
323.95%
AI Spotlight on MCK
Company Description
McKesson Corporation provides healthcare services in the United States and internationally.It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS).The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products.
This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies.The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada.The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers.
The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions.McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Market Data
| Last Price | 604.6 |
| Change Percentage | 0.24% |
| Open | 605.98 |
| Previous Close | 603.18 |
| Market Cap ( Millions) | 76748 |
| Volume | 473344 |
| Year High | 637.51 |
| Year Low | 464.42 |
| M A 50 | 594.06 |
| M A 200 | 561.78 |
Financial Ratios
| FCF Yield | 6.12% |
| Dividend Yield | 0.44% |
| ROE | -115.33% |
| Debt / Equity | -239.28% |
| Net Debt / EBIDTA | 97.66% |
| Price To Book | -25.79 |
| Price Earnings Ratio | 30.68 |
| Price To FCF | 16.34 |
| Price To sales | 0.23 |
| EV / EBITDA | 16.89 |
News
- Jan -30 - McKesson Corporation Declares Quarterly Dividend
- Jan -28 - McKesson (MCK) Stock Drops Despite Market Gains: Important Facts to Note
- Jan -23 - McKesson's Practice Insights Selected as a 2025 Qualified Clinical Data Registry by Centers for Medicare & Medicaid Services
- Jan -22 - McKesson (MCK) Stock Declines While Market Improves: Some Information for Investors
- Jan -21 - MCK Stock Gains 4% in 3 Weeks: Should You Buy, Hold or Sell?
- Jan -13 - McKesson (MCK) Surpasses Market Returns: Some Facts Worth Knowing
- Jan -02 - McKesson Stock Declines Post Divestiture of Canada-Based Businesses
- Dec -31 - McKesson Corporation Completes Divestiture of Canada-Based Rexall and Well.ca Businesses
- Dec -30 - 5 Beaten-Down MedTech Stocks Set to Rebound in 2025
- Dec -30 - McKesson Corporation Announces Third Quarter Fiscal 2025 Earnings Release Date and Participation in January Conference
- Dec -20 - 4 Large Cap MedTech Stocks to Keep Winning Streaks Alive in 2025
- Dec -20 - Best Growth Stocks to Buy for December 20th
- Dec -20 - Buy 5 Value Stocks Amid Strong Upside Potential in the Short Term
- Dec -19 - 3 Top Ranked Stocks to Buy for 2025 (GPOR, MCK, MRVL)
- Dec -19 - Best Growth Stocks to Buy for December 19th
- Dec -18 - Best Growth Stocks to Buy for December 18th
- Dec -18 - Best Value Stocks to Buy for December 18th
- Dec -16 - Prescription for Profits: 3 Must-Buy Healthcare Stocks Before 2025
- Dec -16 - Best Growth Stocks to Buy for December 16th
- Dec -16 - Best Value Stocks to Buy for December 16th
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> United States Pharmaceutical
Expected Growth : 9 %
What the company do ?
The United States Pharmaceutical segment of McKesson Corporation distributes branded, generic, and specialty pharmaceuticals, as well as other healthcare-related products to pharmacies, hospitals, and other healthcare providers.
Why we expect these perspectives ?
McKesson Corporation's 9% growth in the United States Pharmaceutical segment is driven by increasing demand for specialty drugs, expansion of its oncology and biosimilar offerings, and strategic acquisitions. Additionally, the company's investments in technology and data analytics have improved operational efficiency, enabling it to capitalize on the growing need for healthcare services.
Segment n°2 -> International
Expected Growth : 11 %
What the company do ?
McKesson International is a global healthcare company that provides medical supplies, pharmaceuticals, and healthcare technology solutions to healthcare providers and patients worldwide.
Why we expect these perspectives ?
McKesson's International segment growth of 11% is driven by increasing demand for healthcare services in emerging markets, strategic acquisitions, and expansion of its distribution network. Additionally, the company's focus on providing value-added services, such as pharmaceutical sourcing and logistics, has contributed to its growth in this segment.
Segment n°3 -> Medical-Surgical Solutions
Expected Growth : 8 %
What the company do ?
Medical-Surgical Solutions from McKesson Corporation provides medical supplies, equipment, and pharmaceuticals to healthcare providers, helping them deliver high-quality patient care.
Why we expect these perspectives ?
McKesson's Medical-Surgical Solutions segment growth is driven by increasing demand for healthcare services, an aging population, and a shift towards value-based care. Additionally, the company's strategic acquisitions, investments in digital solutions, and expansion into new markets have contributed to its 8% growth.
Segment n°4 -> Prescription Technology Solutions
Expected Growth : 12 %
What the company do ?
Prescription Technology Solutions from McKesson Corporation provides healthcare technology solutions for pharmacies, hospitals, and healthcare systems to manage patient care and medication therapy.
Why we expect these perspectives ?
McKesson's Prescription Technology Solutions segment growth is driven by increasing adoption of digital healthcare solutions, rising demand for prescription automation, and expansion into new markets. Additionally, the company's strategic partnerships, innovative product offerings, and investments in artificial intelligence and machine learning are contributing to its 12% growth.
Mckesson Corporation Products
| Product Range | What is it ? |
|---|---|
| Pharmaceutical Distribution | McKesson's pharmaceutical distribution business provides prescription and over-the-counter medications, as well as vaccines and biopharmaceuticals, to pharmacies, hospitals, and clinics. |
| Medical-Surgical Distribution | McKesson's medical-surgical distribution business provides medical supplies, equipment, and services to healthcare providers, including hospitals, surgery centers, and physician offices. |
| Technology and Analytics | McKesson's technology and analytics business provides healthcare technology solutions, including electronic health records, revenue cycle management, and analytics, to healthcare providers. |
| Oncology and Specialty Care | McKesson's oncology and specialty care business provides specialty pharmaceuticals, medical supplies, and services to oncologists, hematologists, and other specialty physicians. |
| Retail Pharmacy Solutions | McKesson's retail pharmacy solutions business provides technology, services, and support to independent pharmacies, helping them to operate efficiently and effectively. |
McKesson Corporation's Porter Forces
Threat Of Substitutes
McKesson Corporation operates in the healthcare industry, where there are limited substitutes for its pharmaceutical distribution and medical-surgical distribution services. However, the company faces some threat from online pharmacies and other alternative distribution channels.
Bargaining Power Of Customers
McKesson Corporation's customers, including hospitals, clinics, and pharmacies, have limited bargaining power due to the company's strong market position and diversified customer base.
Bargaining Power Of Suppliers
McKesson Corporation's suppliers, including pharmaceutical manufacturers, have some bargaining power due to the company's dependence on them for products. However, the company's large scale and diversified supplier base mitigate this risk.
Threat Of New Entrants
The threat of new entrants in the pharmaceutical distribution and medical-surgical distribution industries is low due to the high barriers to entry, including regulatory hurdles and the need for significant capital investment.
Intensity Of Rivalry
The pharmaceutical distribution and medical-surgical distribution industries are highly competitive, with several large players competing for market share. McKesson Corporation faces intense rivalry from companies such as AmerisourceBergen and Cardinal Health.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 152.01% |
| Debt Cost | 4.09% |
| Equity Weight | -52.01% |
| Equity Cost | 6.19% |
| WACC | 2.99% |
| Leverage | -292.29% |
McKesson Corporation : Quality Control
McKesson Corporation passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| COR | Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and … |
| CAH | Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, … |
| REGN | Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular … |
| ABBV | AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat … |
| JNJ | Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
AbbVie
A-Score
1-Year Total Return ->
🥈
Cencor
A-Score
1-Year Total Return ->
🥉
Cardinal Health
A-Score
1-Year Total Return ->
4
J&J
A-Score
1-Year Total Return ->
5
McKesson
A-Score
1-Year Total Return ->
6
